International Journal of Clinical Research

Objective To investigate the clinical efficacy of flupentixol and melitracen in patients with functional dyspepsia accompanied by anxiety and depressive symptoms, and to evaluate its comprehensive effects on gastrointestinal symptom relief and emotional improvement. Methods From May 2021 to May 2025, a total of 80 patients meeting the diagnostic criteria for functional dyspepsia with anxiety and depressive symptoms were consecutively enrolled and randomly divided into a control group and an experimental group, with 40 cases in each. The control group received conventional symptomatic treatment for the digestive system, while the experimental group additionally received flupentixol and melitracen tablets. The Gastrointestinal Symptom Rating Scale (GSRS), Hamilton Anxiety Scale (HAMA), and Hamilton Depression Scale (HAMD) were used to evaluate efficacy. Adverse reactions were recorded, and the degree of gastrointestinal symptom relief and psychological improvement after treatment was compared between groups. Results The experimental group showed more significant improvement in gastrointestinal symptoms such as epigastric discomfort, bloating, and belching compared with the control group. The reductions in anxiety and depression scores were more pronounced, and the overall clinical efficacy rate was higher. The experimental group also demonstrated better treatment compliance, greater improvements in daily quality of life, and lower incidence of adverse reactions with good tolerability. Conclusion Flupentixol and melitracen can effectively relieve gastrointestinal symptoms and improve anxiety and depressive states in patients with functional dyspepsia, with high clinical application value, highlighting its advantages in the management of comorbid somatic and psychological conditions.

Flupentixol and melitracen; Functional dyspepsia; Anxiety; Depression